Terms: = Head and neck cancer AND STIL, SIL, 6491, ENSG00000123473, Q15468 AND Prognosis
22 results:
1. Chemoradiation for oesophageal cancer: the choice of treatment modality.
Kitti PM; Faltinova M; Kauppi J; Räsänen J; Saarto T; Seppälä T; Anttonen AM
Radiat Oncol; 2023 May; 18(1):93. PubMed ID: 37259100
[TBL] [Abstract] [Full Text] [Related]
2. Comparison of the prognoses of laryngeal preneoplastic lesions based on Ljubljana and World Health Organization classifications.
Doğan E; Boran C; Cevizci MC; Sarıoğlu S
Turk J Med Sci; 2023 Feb; 53(1):396-404. PubMed ID: 36945918
[TBL] [Abstract] [Full Text] [Related]
3. [Monitoring Blood Markers to Predict Nivolumab Effectiveness in Esophageal Carcinoma].
Funatsuya T; Tanaka Y; Honma M; Fukuoka H; Takahashi M
Gan To Kagaku Ryoho; 2022 Oct; 49(10):1139-1141. PubMed ID: 36281612
[TBL] [Abstract] [Full Text] [Related]
4. Histologic evaluation of host immune microenvironment and its prognostic significance in oral tongue squamous cell carcinoma: a comparative study on lymphocytic host response (LHR) and tumor infiltrating lymphocytes (TILs).
Xu B; Salama AM; Valero C; Yuan A; Khimraj A; Saliba M; Zanoni DK; Ganly I; Ghossein R; Patel SG; Katabi N
Pathol Res Pract; 2021 Dec; 228():153473. PubMed ID: 34059347
[TBL] [Abstract] [Full Text] [Related]
5. Tumor infiltrating lymphocyte signature is associated with single nucleotide polymorphisms and predicts survival in esophageal squamous cell carcinoma patients.
Suo C; Chen H; Binczyk F; Zhao R; Fan J; Yang X; Yuan Z; Kreil D; Łabaj P; Zhang T; Lu M; Jin L; Polańska J; Chen X; Ye W
Aging (Albany NY); 2021 Apr; 13(7):10369-10386. PubMed ID: 33819921
[TBL] [Abstract] [Full Text] [Related]
6. Comparative p16
Tsiambas E; Riziotis C; Mastronikolis NS; Peschos D; Mortakis A; Kyroysis G; Mastronikolis SN; Batistatou A; Lazaris AC; Patsouris E; Ragos V
Anticancer Res; 2018 Oct; 38(10):5805-5810. PubMed ID: 30275203
[TBL] [Abstract] [Full Text] [Related]
7. Proinflammatory cytokines as serum biomarker in oral carcinoma-A prospective multi-biomarker approach.
Schiegnitz E; Kämmerer PW; Schön H; Blatt S; Berres M; Sagheb K; Al-Nawas B
J Oral Pathol Med; 2018 Mar; 47(3):268-274. PubMed ID: 29272054
[TBL] [Abstract] [Full Text] [Related]
8. The Diagnostic and Prognostic Value of sil-2R as an Immune Biomarker in head and neck cancers.
Gross M; Meirovich A; Rachmut J; Kalichman I; Peretz T; Eliashar R; Barak V
Anticancer Res; 2016 Aug; 36(8):4347-52. PubMed ID: 27466555
[TBL] [Abstract] [Full Text] [Related]
9. Stomal recurrence in head and neck cancer patients with temporary tracheostomy.
Esteller E; Agüero A; Martel M; López M; Quer M; León X
Auris Nasus Larynx; 2014 Oct; 41(5):467-70. PubMed ID: 24602695
[TBL] [Abstract] [Full Text] [Related]
10. Slug is a predictor of poor prognosis in esophageal squamous cell carcinoma patients.
Hasan MR; Sharma R; Saraya A; Chattopadhyay TK; DattaGupta S; Walfish PG; Chauhan SS; Ralhan R
PLoS One; 2013; 8(12):e82846. PubMed ID: 24367561
[TBL] [Abstract] [Full Text] [Related]
11. Novel and simple prognostic index for nasal natural killer/T-cell lymphoma.
Hanakawa H; Orita Y; Sato Y; Takao S; Marunaka H; Morishita T; Yamashita Y; Hori Y; Domae S; Inokuchi I; Akagi S; Kondo E; Iwaki N; Motomiya K; Okumura H; Yoshino T; Nishizaki K
Head Neck; 2014 Apr; 36(4):551-6. PubMed ID: 23780926
[TBL] [Abstract] [Full Text] [Related]
12. Clinical significance of measuring levels of tumor necrosis factor-alpha and soluble interleukin-2 receptor in nasopharyngeal carcinoma.
Hsiao SH; Lee MS; Lin HY; Su YC; Ho HC; Hwang JH; Lee CC; Hung SK
Acta Otolaryngol; 2009 Dec; 129(12):1519-23. PubMed ID: 19922107
[TBL] [Abstract] [Full Text] [Related]
13. [A case of nasal NK/T cell lymphoma presenting with bilateral giant adrenal tumors].
Toba A; Tamura Y; Osajima Y; Kinbara Y; Sato M; Yamaga R; Hashimoto R; Mori S; Miyakoshi S; Ota M; Ito H; Araki A
Nihon Ronen Igakkai Zasshi; 2008 Nov; 45(6):660-5. PubMed ID: 19179800
[TBL] [Abstract] [Full Text] [Related]
14. [Seric soluble interleukin-2 receptor alpha in nasopharyngeal carcinoma in Tunisia. Prospective study about 45 cases].
Jmal A; Ghanem A; Boussen H; Gara Y; Abaza H; Gara S; Harzallah L; Ladgham A; Guemira F
Tunis Med; 2007 Aug; 85(8):651-4. PubMed ID: 18254285
[TBL] [Abstract] [Full Text] [Related]
15. Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review.
Bien E; Balcerska A
Biomarkers; 2008 Feb; 13(1):1-26. PubMed ID: 17906988
[TBL] [Abstract] [Full Text] [Related]
16. [Immunodetections and analysis of peripheral blood for patients with oral cancer undergoing operation].
Ye DX; Xu Q; Chen WT; Zhu HG; Lin GC; Jiang CH; Qiu WL
Shanghai Kou Qiang Yi Xue; 2004 Apr; 13(2):83-6. PubMed ID: 15133544
[TBL] [Abstract] [Full Text] [Related]
17. [The dynamic study of cytokines pre- and postoperation in patients with carcinoma of larynx].
Wang Q; Feng Y; Zhang X; Wang H; Xu D
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2001 Jun; 15(6):255-7. PubMed ID: 12541774
[TBL] [Abstract] [Full Text] [Related]
18. Effect of platelet activating factor and butyrate on the expression of interleukin-2 receptor alpha in nasopharyngeal carcinoma cells.
Tsai MH; Chiou SH; Chow KC
Int J Oncol; 2001 Nov; 19(5):1049-55. PubMed ID: 11605008
[TBL] [Abstract] [Full Text] [Related]
19. Clinical significance of serum soluble interleukin 2 receptor-alpha in esophageal squamous cell carcinoma.
Wang LS; Chow KC; Li WY; Liu CC; Wu YC; Huang MH
Clin Cancer Res; 2000 Apr; 6(4):1445-51. PubMed ID: 10778976
[TBL] [Abstract] [Full Text] [Related]
20. [The level of soluble interleukin 2 receptor in esophageal carcinoma patients before and after radiotherapy].
Liu X; An H; Jiang Y
Zhonghua Zhong Liu Za Zhi; 1995 Mar; 17(2):97-9. PubMed ID: 7656815
[TBL] [Abstract] [Full Text] [Related]
[Next]
